Search
olaratumab (Lartruvo)
Indications:
- in combination with doxorubicin
- advanced soft tissue sarcomas not amenable to curative treatment with radiotherapy or surgery
Dosage:
injection 10 mg/ml
Mechanism of action:
- PDGFRA inhibitor
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- Sheng JY, Movva S.
Systemic Therapy for Advanced Soft Tissue Sarcoma.
Surg Clin North Am. 2016 Oct;96(5):1141-56.
PMID: 27542647
- Highlights of Prescribing Information.
LARTRUVO (olaratumab) injection, for intravenous use.
http://pi.lilly.com/us/lartruvo-uspi.pdf